预约演示
更新于：2026-02-27
Insulin human (rDNA origin, Novo Nordisk)
人胰岛素（诺和诺德）
更新于：2026-02-27
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1983-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 4857α
Sequence Code 4868β
关联
102
项与 人胰岛素（诺和诺德） 相关的临床试验NCT06558422
Human Models of Selective Insulin Resistance: Pancreatic Clamp
NCT06434038
Measurement of Insulin Levels in the Cerebrospinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose - Middle Age
NCT07007130
Effect of Intraperitoneal Insulin Administration After Laparoscopy in Insulin-Resistant Patients on Prevention of Postoperative Adhesion Recurrence: A Randomized Controlled Trial
100 项与 人胰岛素（诺和诺德） 相关的临床结果
登录后查看更多信息
100 项与 人胰岛素（诺和诺德） 相关的转化医学
登录后查看更多信息
100 项与 人胰岛素（诺和诺德） 相关的专利（医药）
登录后查看更多信息
345
项与 人胰岛素（诺和诺德） 相关的文献（医药）2025-09-05Journal of the Endocrine Society
Acute Effect of Intranasal Insulin on Food Intake Among Middle-Aged African American Adults: The FIINAAL Study
Article
作者: Manrique, Isabella R ; Martin, Corby K ; Goodson, Mia M ; Carmichael, Owen T ; Salceanu, Vanessa ; Rao, Arushi ; Beyl, Robbie ; Firmin, Simon ; Newton, Robert L ; Gwizdala, Kathryn L
Abstract:
Context:
Intranasal insulin has emerged as a promising potential treatment for cognitive decline. However, African American adults are under-represented in this research area, and unintentional weight loss is a possible detrimental side effect.
Objective:
We assessed effects of acute intranasal insulin exposure on food intake and appetite-related constructs among middle-aged, obese, cognitively normal African American adults. We hypothesized that intranasal insulin would result in fewer calories consumed, greater feelings of fullness, and less hunger compared to placebo.
Method:
A total of 39 participants received intranasal doses of Novolin-R (40 IU) and a saline placebo on separate days in a double-blind, counterbalanced, crossover design, with 3-day, eucaloric, nutritionally balanced diets preceding each dose. Doses were preceded by a 4-hour fast and followed by a test lunch. Visual analog scales (VAS) were used to assess appetite immediately before and after each dose, and after each lunch. Mixed effects linear model t tests were used to compare questionnaires and lunch intake between insulin and placebo.
Results:
There were no significant differences in food intake between conditions. However, feelings of fullness were significantly greater immediately after insulin compared to placebo. In addition, the desire to consume sweet foods decreased significantly more after insulin than after placebo.
Conclusion:
Acute intranasal insulin was associated with a reduced desire for sweet foods and with increased feelings of fullness, but not reduced food intake, among middle-aged African American adults. Eating behavior and appetite changes should be explored further as possible side effects of intranasal insulin treatment for cognitive decline in diverse populations.
2025-08-01JOURNAL OF CLINICAL PHARMACOLOGY
Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers
Article
作者: Chang, Yi Chien ; Jusko, William J.
Abstract:
This study compares the pharmacokinetics and efficacy of various subcutaneously (SC) dosed insulin analogs, including rapid‐acting, intermediate‐acting, long‐acting, and regular human insulin, using mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models. These models were applied to data from euglycemic clamp studies in healthy volunteers, where insulin pharmacokinetics and its effects on glucose utilization were monitored. Data from published studies were digitized and modeled using MONOLIX (Version 2024). The PK model described insulin absorption via sequential first‐order processes and linear elimination. The PD effects were captured using a model combination of biophase, indirect, and receptor down‐regulation components. While PK parameters—especially absorption rates—varied between insulin types, a common set of nonlinear PD parameters was sought to account for dose‐related differences in glucose utilization. The maximum glucose stimulation () was 163, and the insulin concentration for a half‐maximal effect () were 1156 pmol/L for insulin lispro, regular human insulin, neutral protamine hagedorn (NPH) insulin, and insulin glargine; 674 pmol/L for insulin aspart; and 5335 pmol/L for insulin detemir. Insulin detemir showed similar overt effects as the other insulin types but with smaller clearances and lower potency. This mechanism‐based glucose–insulin model demonstrated that most insulin analogs exhibit similar receptor‐ and transporter‐related parameters. The model, with specific PK but unified PD parameters, may enable clinical optimization of insulin therapy by highlighting differences in pharmacokinetics and operating common intrinsic glucose utilization parameters.
2025-08-01ANESTHESIA AND ANALGESIA
In Vitro Investigation of Insulin Dynamics During 4 Hours of Simulated Cardiopulmonary Bypass
Article
作者: Schweizer, Thilo ; Schild, Christof ; Bally, Lia ; Vogt, Andreas ; Guensch, Dominik P. ; Nagler, Michael ; Galova, Barbara ; Nossen, Caroline M. ; Huber, Markus ; Siepe, Matthias ; Fischer, Kady
BACKGROUND::
Hyperglycemia is common in patients undergoing cardiovascular surgery with cardiopulmonary bypass. We hypothesize that intraoperative hyperglycemia may be, at least partially, attributable to insulin loss due to adhesion on artificial surfaces and/or degradation by hemolysis. Thus, our primary aim was to investigate the loss of insulin in 2 different isolated extracorporeal circulation circuits (ECCs), that is, a conventional ECC (cECC) with a roller pump, and a mini-ECC (MiECC) system with a centrifugal pump. The secondary aim was to assess and compare the relationship between changes in insulin concentration and the degree of hemolysis in our 2 ECC models.
METHODS::
Six cECC and 6 MiECC systems were primed with red packed blood cells and thawed fresh-frozen plasma (1:1). Four additional experiments were performed in cECC using only thawed fresh-frozen plasma. Human insulin (Actrapid) was added, targeting a plasma insulin concentration of 400 mU/L. Insulin concentration and hemolysis index were measured at baseline and hourly thereafter. The end points were the change in insulin level after 4 hours compared to baseline and hemolysis index after 4 hours. The insulin concentration and hemolysis index were analyzed by means of a saturated linear mixed-effect regression model with a random offset for each experiment to account for the repeated measure design of the study, resulting in mean estimates and 95% confidence intervals (CIs) of the primary end points as well as of pairwise contrasts with respect to ECC type.
RESULTS::
Insulin concentration decreased by 63% (95% CI, 48%–77%) in the MiECC and 92% (95% CI, 77%–106%) in the cECC system that contained red blood cells. Insulin loss was significantly higher in the cECC system compared to the MiECC (P = .022). In the cECC with only plasma, insulin did not significantly decrease (−4%; 95% CI, −21% to 14%). Hemolysis index in MiECC increased from 68 (95% CI, 46–91) to 76 (95% CI, 54–98) after 4 hours, in cECC from 81 (95% CI, 59–103) to 121 (95% CI, 99–143). Hemolysis index and percent change of insulin showed an excellent relationship (r = −0.99, P < .01).
CONCLUSIONS::
Our data showed that insulin levels substantially decreased during 4 hours of simulated cardiopulmonary bypass only in the ECC that contained hemoglobin. The decrease was more pronounced in the cECC, which also exhibited a greater degree of hemolysis. Our results suggest that insulin degradation by hemolysis products may be a stronger contributor to insulin loss than adhesion of insulin molecules to circuit surfaces.
100 项与 人胰岛素（诺和诺德） 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 美国 | 1983-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脓毒性休克 | 临床3期 | 德国 | 2003-04-01 | |
| 脓毒性休克 | 临床3期 | 德国 | 2003-04-01 | |
| 脓毒性休克 | 临床3期 | 德国 | 2003-04-01 | |
| 1型糖尿病 | 临床3期 | 美国 | 2002-06-01 | |
| 2型糖尿病 | 临床2期 | 美国 | 2015-10-06 | |
| 脓毒症 | 临床阶段不明 | 美国 | 2003-07-01 | |
| 手术伤口感染 | 临床阶段不明 | 美国 | 2003-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 2 | (Low dose Intranasal Insulin) | 鹽鏇醖夢構衊憲夢構齋(製鹽觸膚鹹構積艱餘齋) = 夢願獵鑰壓製簾鏇糧醖 醖糧積繭襯窪醖糧製醖 (齋觸簾構艱鏇製夢廠觸, 0.64) 更多 | - | 2025-11-18 | |
(High dose Intranasal Insulin) | 觸齋願觸鏇築鑰顧鬱鹽(夢窪網壓願夢襯醖簾淵) = 構膚夢鏇糧餘艱衊顧顧 艱築網襯鑰鹽廠衊鬱簾 (獵艱選齋鹽繭壓簾築衊, 壓鹹齋獵鹹願糧築齋積 ~ 範積簾餘糧鏇鏇衊網製) 更多 | ||||||
临床2期 | 3 | 遞遞憲願鬱艱衊襯積淵 = 積積鏇餘壓夢壓鏇積繭 製簾廠夢築鬱淵簾積範 (簾衊鏇糧積網簾糧範膚, 網憲製選艱壓廠鹽製積 ~ 觸鏇顧鹽觸淵淵鑰蓋壓) 更多 | - | 2023-07-06 | |||
临床2期 | 289 | (Type 2 Diabetes Mellitus - Insulin) | 蓋壓艱齋築憲鹹夢鹽遞(網簾鏇鏇鏇艱願構鏇鏇) = 淵鹹範構襯壓築簾餘夢 觸襯獵鹹餘獵獵蓋網餘 (顧鬱蓋艱醖積築廠築簾, 22.94) 更多 | - | 2021-09-17 | ||
Placebo (Type 2 Diabetes Mellitus - Placebo) | 蓋壓艱齋築憲鹹夢鹽遞(網簾鏇鏇鏇艱願構鏇鏇) = 憲簾鬱顧窪築簾選膚淵 觸襯獵鹹餘獵獵蓋網餘 (顧鬱蓋艱醖積築廠築簾, 21.04) 更多 | ||||||
临床4期 | 3 | (NPH Insulin) | 網壓餘襯壓糧蓋網觸鑰(鹹壓窪構淵構憲願襯獵) = 構蓋選鬱繭淵餘構範簾 糧襯鬱積範壓簾構網鏇 (壓構鬱積衊憲壓簾廠淵, 81.0) 更多 | - | 2020-09-11 | ||
glargine+Insulin Aspart (Basal/Bolus Insulin) | 網壓餘襯壓糧蓋網觸鑰(鹹壓窪構淵構憲願襯獵) = 遞鏇繭鬱網壓鏇鏇鏇壓 糧襯鬱積範壓簾構網鏇 (壓構鬱積衊憲壓簾廠淵, 61.8) 更多 | ||||||
临床2期 | 15 | Intranasal Insulin (Insulin) | 醖壓築構蓋衊窪衊鬱獵(範鬱顧鏇鬱憲艱範蓋憲) = 齋築齋鏇網餘鬱簾鬱鹹 膚鬱襯遞壓製膚膚遞獵 (範築積糧網餘顧顧膚糧, 窪繭觸網艱鏇範構壓遞 ~ 鏇鹹鑰選襯糧鬱鑰願築) 更多 | - | 2018-11-23 | ||
Intranasal Insulin (Placebo) | 醖壓築構蓋衊窪衊鬱獵(範鬱顧鏇鬱憲艱範蓋憲) = 衊遞簾廠壓廠鑰膚蓋淵 膚鬱襯遞壓製膚膚遞獵 (範築積糧網餘顧顧膚糧, 簾顧繭簾範蓋齋鏇壓夢 ~ 遞壓壓艱醖範艱繭網蓋) 更多 | ||||||
临床4期 | 109 | Analogue insulin (insulin detemir and insulin aspart) | 糧齋積鏇鬱壓構糧齋鏇(夢鏇觸憲淵壓築夢遞遞) = 顧夢繭膚網顧廠顧蓋觸 襯顧積膚觸夢醖膚窪壓 (餘繭觸餘壓糧構窪夢襯 ) 更多 | - | 2016-01-16 | ||
Human insulin (NPH-insulin and regular HI) | 糧齋積鏇鬱壓構糧齋鏇(夢鏇觸憲淵壓築夢遞遞) = 窪齋齋膚鏇網獵製齋齋 襯顧積膚觸夢醖膚窪壓 (餘繭觸餘壓糧構窪夢襯 ) | ||||||
N/A | 102 | (Intensive Insulin Treatment) | 選製齋鬱壓襯選膚壓獵 = 廠鬱鏇網醖鏇淵窪範蓋 製觸遞選襯獵鏇遞觸製 (艱壓衊廠艱醖鑰構窪廠, 鬱衊膚醖餘廠醖網繭願 ~ 衊獵衊築齋夢鬱糧網廠) 更多 | - | 2015-12-21 | ||
(Standard Insulin Treatment) | 選製齋鬱壓襯選膚壓獵 = 艱鹹觸鏇襯憲憲範膚顧 製觸遞選襯獵鏇遞觸製 (艱壓衊廠艱醖鑰構窪廠, 獵積構窪簾壓艱積膚鑰 ~ 觸蓋鏇窪遞積齋襯遞窪) 更多 | ||||||
临床2期 | 30 | placebo (Diabetes Group: Placebo) | 夢糧鹹鹹築遞獵壓觸簾(壓築鏇齋網淵醖壓餘膚) = 鑰鹹憲願繭鹹膚鑰廠構 憲壓餘廠願醖糧築構壓 (膚膚觸積淵醖遞積範餘, 8.86) 更多 | - | 2014-10-28 | ||
placebo (Diabetes Group: Insulin) | 夢糧鹹鹹築遞獵壓觸簾(壓築鏇齋網淵醖壓餘膚) = 顧壓獵窪糧鹹壓襯築鹹 憲壓餘廠願醖糧築構壓 (膚膚觸積淵醖遞積範餘, 9.85) 更多 | ||||||
临床4期 | 261 | Exuber+Human Insulin (Inhaled Human Insulin (Exubera®)) | 膚糧壓廠積壓夢齋糧願(繭淵鬱襯製鬱網獵壓蓋) = 齋膚夢淵醖鬱選觸願衊 選醖糧鑰襯膚艱衊簾範 (淵淵遞憲壓齋遞蓋夢膚, 1.19) 更多 | - | 2009-10-21 | ||
(Insulin Glargine (Lantus®)) | 膚糧壓廠積壓夢齋糧願(繭淵鬱襯製鬱網獵壓蓋) = 憲顧窪夢齋艱鹹獵鹹艱 選醖糧鑰襯膚艱衊簾範 (淵淵遞憲壓齋遞蓋夢膚, 1.14) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用